Full Text View
Tabular View
No Study Results Posted
Related Studies
Clinical Trial of a Therapeutic Vaccine With NY-ESO-1 in Combination With the Adjuvant Monophosphoryl Lipid A (MPLA)
This study is not yet open for participant recruitment.
Verified April 2012 by Instituto de Investigação em Imunologia
Study NCT01584115   Information provided by Instituto de Investigação em Imunologia

First Received on April 21, 2012.   Last Updated on April 24, 2012   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Cancer.
Melanoma.
Ovarian Cancer.
Lung Cancer.
Additional conditions recognized in this trial
Lung Neoplasms
Melanoma
Ovarian Neoplasms
More general conditions related to this trial
Adnexal Diseases
Endocrine Gland Neoplasms
Endocrine System Diseases
Genital Diseases, Female
Genital Neoplasms, Female
Gonadal Disorders
Lung Diseases
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Germ Cell and Embryonal
Neoplasms, Nerve Tissue
Neuroectodermal Tumors
Neuroendocrine Tumors
Nevi and Melanomas
Ovarian Diseases
Respiratory Tract Diseases
Respiratory Tract Neoplasms
Thoracic Neoplasms
Urogenital Neoplasms
Interventions listed in this trial
NY-ESO-1 combined with MPLA
NY-ESO-1 combined with MPLA vaccine
Additional drug interventions recognized in this trial
Monophosphoryl lipid A
More general drug interventions related to this trial
Adjuvants, Immunologic
Immunologic Factors
Pharmacologic Actions
Physiological Effects of Drugs
Sponsors listed in this trial
Instituto de Investigação em Imunologia
Butantan Institute


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services